Adjunctive Minocycline for Treatment of Posttraumatic Stress Disorder

Anna Gerst, Tej Murthy, Alisandrea Elson, David Driscoll, Marvin J. Bittner, Sriram Ramaswamy

Research output: Contribution to journalArticlepeer-review


INTRODUCTION: Posttraumatic stress disorder (PTSD) is a chronic, debilitating anxiety disorder. While there is evidence that antibiotics such as minocycline may help to improve symptoms in some psychiatric disorders, no human studies have evaluated their potential as a treatment for PTSD. METHODS: We present results from 4 men aged 33 to 59 years who completed a 12-week pilot, prospective, nonrandomized, open-label clinical trial of adjunctive minocycline for veterans diagnosed with PTSD. RESULTS: All 4 patients showed reduction in PTSD symptoms at the end of the 12-week study, and 3 patients showed reduction in depression symptoms. Observed changes in inflammatory biomarkers are discussed. DISCUSSION: Previous studies have reported increased inflammation in PTSD, though evidence of a potential therapeutic effect of minocycline for PTSD has not been reported previously in humans. CONCLUSION: These findings suggest that antibiotics like minocycline may help to reduce symptoms of PTSD, though further investigation is needed to confirm these findings.

Original languageEnglish (US)
Pages (from-to)321-324
Number of pages4
JournalWMJ : official publication of the State Medical Society of Wisconsin
Issue number4
StatePublished - Dec 1 2021

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Adjunctive Minocycline for Treatment of Posttraumatic Stress Disorder'. Together they form a unique fingerprint.

Cite this